Can berry compounds tame inflammation during colorectal cancer care?
NCT ID NCT07819539
First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time
Summary
Researchers at Jagiellonian University are studying whether a supplement made from freeze-dried black raspberries and strawberries affects inflammation in people over 65 receiving treatment for colorectal cancer. About 70 participants take the anthocyanin-rich supplement for 21 days alongside their standard cancer care. The team measures changes in inflammatory markers such as CRP and IL-6, and tracks how well participants tolerate the supplement.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- an anthocyanin-rich freeze-dried black raspberry and strawberry supplement
- What this could lead to
- If it works, this could point toward a low-cost dietary supplement that helps calm inflammation during colorectal cancer treatment in older adults.
- What could go wrong
- This is a small, open-label study with no placebo group, so any changes in inflammatory markers could reflect other factors. Berry supplements can also interact with medications or cause digestive upset.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
70 people
The number who actually took part.
- Started
-
May 2023
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
65 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * (1) histologically confirmed primary colorectal adenocarcinoma; (2) qualification for surgical treatment, neoadjuvant chemoradiotherapy, or systemic chemotherapy; (3) ability to receive oral supplementation; and (4) Eastern Cooperative Oncology Group (ECOG) performance status ≤2. (5)Age ≥65 years Exclusion Criteria: * (1) gastrointestinal obstruction; (2) advanced cardiac or respiratory failure; (3) severe renal or hepatic insufficiency; and (4) food allergies or hypersensitivity that could interfere with administration of the study supplement.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal adenocarcinoma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tarnów Oncology Centre
Tarnów, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to why some cancer treatments work better
- Burning the edges: a new way to stop colon polyps from coming back
- Missed Follow-Up colonoscopies: do they raise the risk of advanced growths?
- A 2.2 mm scope could spot cancerous tissue in minutes, not days
- Experimental drug put to the test against Hard-to-Treat GI cancers
- The gatekeepers of tumors: scientists probe how blood vessels let immune cells in